Skip to main content

24-10-2017 | Rheumatoid arthritis | Review | Article

Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis?

Arthritis Research & Therapy

Authors: Vasco C. Romão, Edward M. Vital, João Eurico Fonseca, Maya H. Buch

Publisher: BioMed Central


Individualising biologic disease-modifying anti-rheumatic drugs (bDMARDs) to maximise outcomes and deliver safe and cost-effective care is a key goal in the management of rheumatoid arthritis (RA). Investigation to identify predictive tools of bDMARD response is a highly active and prolific area of research. In addition to clinical phenotyping, cellular and molecular characterisation of synovial tissue and blood in patients with RA, using different technologies, can facilitate predictive testing. This narrative review will summarise the literature for the available bDMARD classes and focus on where progress has been made. We will also look ahead and consider the increasing use of ‘omics’ technologies, the potential they hold as well as the challenges, and what is needed in the future to fully realise our ambition of personalised bDMARD treatment.

Please log in to get access to this content

Related topics